Oncology Reports · 2014 · 13 citations · 19 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCancer Cell SignalingCytokines In Tumor ImmunityLung CancerMalignant NeoplasmsSignal Transduction In CancerTherapeutic ResistanceAnticancer Drug ResistanceMyd88-dependent SignalingMyeloid Differentiation Primary Response 88 Signaling
The purpose of the present study was to investigate the relationship between myeloid differentiation primary response gene 88 (MyD88) expression and the resistance to paclitaxel of A549 lung cancer cells. In order to achieve MyD88 gene overexpression or knockdown in the A549 cell line, the cells were infected with lentivirus carrying MyD88 gene or shRNA to MyD88. MyD88 mRNA and protein expression was measured by RT-qPCR, immunohistochemistry and western blotting after infection for confirmation. Cell prolife-ration was detected by the WST-1 assay. Flow cytometry was used to measure the cell cycle and apoptosis. The transwell migration assay was used to observe the change of migration of transfected cells. The results showed that the overexpression of MyD88 increased the resistance of lung cancer A549 cells to paclitaxel, while the suppression of MyD88 increased the sensitivity of A549 lung cancer cells to paclitaxel. Following the paclitaxel treatment, a decreased apoptosis and G2 phase ratio, an increased cell migration ratio, and an increased production of IL-8 were found in MyD88‑overexpressed A549 cells. The western blot analysis revealed that Myd88 overexpression resulted in an increased level of Bcl-2 but a decreased level of Bax in A549 cells. These findings suggested that the expression level of MyD88 is closely associated with paclitaxel resistance in A549 lung cancer cells. Thus, the downregulation of MyD88 in A549 cells increased its sensitivity to paclitaxel treatment, whereas the upregulation of MyD88 substantiates its paclitaxel resistance.
19
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.4K citations
TLR-4 Signaling Promotes Tumor Growth and Paclitaxel Chemoresistance in Ovarian Cancer
Michael Kelly, Ayesha B. Alvero, Rui Chen et al. · Cancer Research · 2006 · 490 citations
Life Sciences, Immunology, Oncology +17
Taxol: Mechanisms of Action and Resistancea
Susan Band Horwitz, Leonard Lothstein, James J. Manfredi et al. · Annals of the New York Academy of Sciences · 1986 · 417 citations